LEADER 05404nam 22007815 450 001 9910437839503321 005 20211022170737.0 010 $a3-642-17907-X 024 7 $a10.1007/978-3-642-17907-5 035 $a(CKB)3710000000015831 035 $a(SSID)ssj0000986601 035 $a(PQKBManifestationID)11605182 035 $a(PQKBTitleCode)TC0000986601 035 $a(PQKBWorkID)10937671 035 $a(PQKB)10556191 035 $a(DE-He213)978-3-642-17907-5 035 $a(MiAaPQ)EBC3095814 035 $a(Au-PeEL)EBL3095814 035 $a(CaPaEBR)ebr10969172 035 $a(OCoLC)857279797 035 $a(PPN)172424992 035 $a(EXLCZ)993710000000015831 100 $a20130810d2013 u| 0 101 0 $aeng 135 $aurnn#008mamaa 181 $ctxt 182 $cc 183 $acr 200 10$aDrug Design$b[electronic resource] $eMethodology, Concepts, and Mode-of-Action /$fby Gerhard Klebe 205 $a1st ed. 2013. 210 1$aBerlin, Heidelberg :$cSpringer Berlin Heidelberg :$cImprint: Springer,$d2013. 215 $a1 online resource (496 illus., 333 illus. in color. eReference.) 300 $aBibliographic Level Mode of Issuance: Monograph 311 $a3-642-17908-8 311 $a3-642-17906-1 327 $aPart I  Fundamentals in Drug Research -- 1. Drug Research Yesterday, Today and Tomorrow -- 2. The Role of Serendipity in Drug Research -- 3. Classical Drug Research -- 4. Protein?Ligand Interactions as the Basis for Drug Action -- 5. Optical Activity and Biological Effects -- Part II Discovery and Optimization of Lead Compounds --  6. Screening for Lead Structures -- 7.  Screening Technologies for Lead Discovery -- 8. Optimization of Lead Structures -- 9. Designing prodrugs -- 10. Peptidomimetics -- Part III  Experimental and Theoretical Methods -- 11. Combinatorics: Chemistry With Big Numbers -- 12. Gene Technology in drug research --  13. Experimental Methods of Structure Determination -- 14. The Spatial Structure of Biomolecules -- 15. Molecular Modelling -- 16. Conformational Analysis -- Part IV Structure?Activity Relationships and Design Approaches -- 17.Pharmacophore Hypothesis and Molecular Comparisons -- 18. Quantitative Structure?Activity Relationships -- 19.  From in vitro to in vivo: Optimization of ADME-Tox Properties -- 20. Protein Modeling and Structure-Based Drug Design -- 21.  A Case Study: Structure-Based Inhibtor Design for tRNA-Guanine Transglycosylase -- Part V. Drugs and drug action: Successes of structure-based design -- 22. How drugs act: Concepts for therapy -- 23. Inhibitors of hydrolases With an acyl-enzyme intermediate -- 24. Asparticprotease inhibitors -- 25. Inhibitors of hydrolysing metalloenzymes -- 26. Inhibitors of transferases -- 27. Inhibitors of oxidoreductases -- 28.  Agonists and antagonists of nuclear receptors -- 29. Agonists and antagonists of membrane-bound -- 30. Ligands for channels, pores and transporters -- 31. Ligands for surface receptors -- 32. Biologicals: Peptides, proteins, nucleotides and macrolides as drugs. 330 $aUnique work on structure-based drug design, covering multiple aspects of drug discovery and development. Fully colored, many images, computer animations of 3D structures (these only in electronic form). Makes the spatial aspects of interacting molecules clear to the reader, covers multiple applications and methods in drug design. Structures by mode of action, no therapeutic areas. Of high relevance for academia and industrial research. Focus on gene technology in drug design, omics-technologies computational methods experimental techniques of structure determination multiple examples on mode of action of current drugs, ADME-tox properties in drug development, QSAR methods, combinatorial chemistry, biologicals, ribosome, targeting protein-protein interfaces. 606 $aMedicine 606 $aPharmacology 606 $aPharmaceutical technology 606 $aMedicinal chemistry 606 $aPharmacy 606 $aBiomedicine, general$3https://scigraph.springernature.com/ontologies/product-market-codes/B0000X 606 $aPharmacology/Toxicology$3https://scigraph.springernature.com/ontologies/product-market-codes/B21007 606 $aPharmaceutical Sciences/Technology$3https://scigraph.springernature.com/ontologies/product-market-codes/B21010 606 $aMedicinal Chemistry$3https://scigraph.springernature.com/ontologies/product-market-codes/C28000 606 $aPharmacy$3https://scigraph.springernature.com/ontologies/product-market-codes/F00008 606 $aMedicine/Public Health, general$3https://scigraph.springernature.com/ontologies/product-market-codes/H00007 615 0$aMedicine. 615 0$aPharmacology. 615 0$aPharmaceutical technology. 615 0$aMedicinal chemistry. 615 0$aPharmacy. 615 14$aBiomedicine, general. 615 24$aPharmacology/Toxicology. 615 24$aPharmaceutical Sciences/Technology. 615 24$aMedicinal Chemistry. 615 24$aPharmacy. 615 24$aMedicine/Public Health, general. 676 $a610 700 $aKlebe$b Gerhard$4aut$4http://id.loc.gov/vocabulary/relators/aut$01062131 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910437839503321 996 $aDrug Design$92523068 997 $aUNINA